Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-10-2020 | Chronic Myeloid Leukemia | Original Article

Distribution of BCR–ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia

Authors: Temilola O. Owojuyigbe, Muheez A. Durosinmi, Ramoni A. A. Bolarinwa, Lateef Salawu, Norah O. Akinola, Abdulwaheed A. Ademosun, Oluwayomi T. Bosede

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2020

Abstract

The distribution of BCR–ABL1 transcript variants e13a2 (“b2a2”) and e14a2 (“b3a2”) in Nigerians with chronic myeloid leukemia (CML) had not been previously studied. In addition, there is paucity of data on the impact of BCR–ABL1 transcript variants on clinical presentation and survival in CML patients in Nigeria. The BCR–ABL1 transcript variants were analyzed in 230 Imatinib-treated CML patients at diagnosis. Patients with incomplete data (n = 28), e19a2 (n = 3) and e1a2 (n = 1) were excluded from analysis of transcript variant on disease presentation and survival leaving only 198. The frequencies of BCR–ABL1 transcript variants were 30 (13.0%), 114 (49.6%), 82 (35.7%), three (1.3%) and one (0.4%) for e13a2, e14a2, co-expression of e13a2/e14a2, e19a2 and e1a2, respectively. A significantly higher platelet count was found in patients with e13a2 variant (531.1 ± 563.4 × 10⁹/L) than in those expressing e14a2 (488.2 ± 560.3 × 10⁹/L) or e13a2/e14a2 (320.7 ± 215.8 × 10⁹/L); p = 0.03. No significant differences were found between the variants with regards to gender, age, phase of disease at diagnosis, total white blood cell count, neutrophil percentage, hematocrit, splenomegaly or hepatomegaly. Overall survival was higher but not statistically significant (p = 0.4) in patients with e14a2 variant (134 months) than in e13a2 (119 months) and co-expression of e13a2/e14a2 (115 months). Nigerian CML patients have the highest incidence of co-expression of e13a2 and e14a2. Distinct disease characteristics which contrast with findings from the Western countries were also identified in Nigerians which may be due to genetic factors.

Quintas-Cardama A, Cortes J (2009) Molecular biology of BCR–ABL1-positive chronic myeloid leukemia. Blood 113(8):1619–1630. https://doi.org/10.1182/blood-2008-03-144790CrossRefPubMedPubMedCentral

Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252–265. https://doi.org/10.1002/ajh.24275CrossRefPubMed

Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M et al (2002) Characteristics and outcome of patients with Philadelphia chromosome negative, BCR/ABL negative chronic myelogenous leukemia. Cancer 95(8):1673–1684. https://doi.org/10.1002/cncr.10832CrossRefPubMed

Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y et al (2016) The Philadelphia chromosome in leukemogenesis. Chin J Cancer 35:48. https://doi.org/10.1186/s40880-016-0108-0CrossRefPubMedPubMedCentral

Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW (2006) Comprehensive analysis of BCR–ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res 148(5):249–256. https://doi.org/10.1016/j.trsl.2006.07.002CrossRefPubMed

Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R et al (2016) Impact of BCR–ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269–1275. https://doi.org/10.1182/blood-2015-10-674242CrossRefPubMedPubMedCentral

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C et al (2014) Distinct characteristics of e13a2 versus e14a2 BCR–ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica 99(9):1441–1447. https://doi.org/10.3324/haematol.2013.096537CrossRefPubMedPubMedCentral

Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A et al (2019) The proportion of different BCR–ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33(5):1173–1183. https://doi.org/10.1038/s41375-018-0341-4CrossRefPubMed

Gong Z, Medeiros LJ, Cortes JE, Zheng L, Khoury JD, Wang W et al (2017) Clinical and prognostic significance of e1a2 BCR–ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J 7(7):e583. https://doi.org/10.1038/bcj.2017.62CrossRefPubMedPubMedCentral

10.

Farhat-Maghribi S, Habbal W, Monem F (2016) Frequency of BCR–ABL transcript types in syrian CML patients. J Oncol 2016:8420853. https://doi.org/10.1155/2016/8420853CrossRefPubMedPubMedCentral

11.

Hai A, Kizilbash NA, Zaidi SHH, Alruwaili J, Shahzad K (2014) Differences in structural elements of BCR–ABL oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation 10:108–114. https://doi.org/10.6026/97320630010108CrossRefPubMedPubMedCentral

12.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004. https://doi.org/10.1056/NEJMoa022457CrossRefPubMed

13.

Vieira-Mion AL, Pereira NF, Funke VAM, Pasquini R (2017) Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia. Rev Bras Hematol Hemoter 39(3):210–215. https://doi.org/10.1016/j.bjhh.2017.04.007CrossRefPubMedPubMedCentral

14.

Milojkovic D, Apperley J (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15(24):7519. https://doi.org/10.1158/1078-0432.CCR-09-1068CrossRefPubMed

15.

Bitencourt R, Zalcberg I, Louro ID (2011) Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter 33(6):470–475. https://doi.org/10.5581/1516-8484.20110124CrossRefPubMedPubMedCentral

16.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F et al (2017) The BCR–ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol 92(8):797–805. https://doi.org/10.1002/ajh.24774CrossRefPubMed

17.

de Almeida Filho TP, Maia Filho PA, Barbosa MC, Dutra LLA, de Castro MF, Duarte FB et al (2019) Does BCR–ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? Hematol Transfus Cell Ther 41(2):114–118. https://doi.org/10.1016/j.htct.2018.10.003CrossRefPubMedPubMedCentral

18.

Oyekunle AA, Durosinmi MA, Bolarinwa RA, Owojuyigbe T, Salawu L, Akinola NO (2016) Chronic myeloid leukemia in Nigerian patients: anemia is an independent predictor of overall survival. Clin Med Insights Blood Disord 9:9–13. https://doi.org/10.4137/cmbd.s31562CrossRefPubMedPubMedCentral

19.

D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E et al (2019) The e13a2 BCR–ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer 125(10):1674–1682. https://doi.org/10.1002/cncr.31977CrossRefPubMed

20.

Anand MS, Varma N, Varma S, Rana KS, Malhotra P (2012) Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in North India. Indian J Med Res 135(1):42–48. https://doi.org/10.4103/0971-5916.93423CrossRefPubMedPubMedCentral

21.

Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudhuri U et al (2006) Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol 81(11):845–849. https://doi.org/10.1002/ajh.20682CrossRefPubMed

22.

Muddathir AM, Kordofani AA, Fadl-Elmula IM (2013) Frequency of BCR–ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction. Saudi Med J 34(1):29–33PubMed

23.

Langabeer SE, McCarron SL, Kelly J, Krawczyk J, McPherson S, Perera K et al (2012) Chronic myeloid leukemia with e19a2 BCR–ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol 2012:458716. https://doi.org/10.1155/2012/458716CrossRefPubMedPubMedCentral

24.

Ikeda K, Harada-Shirado K, Matsumoto H, Noji H, Ogawa K, Takeishi Y (2014) Molecular response of e19a2 BCR–ABL1 chronic myeloid leukemia with double Philadelphia chromosome to dasatinib. J Clin Oncol 34(14):e130–e133. https://doi.org/10.1200/JCO.2013.51.1188CrossRefPubMed

25.

Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM et al (2018) Prevalence and outcomes of uncommon BCR–ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol 182(5):693–700. https://doi.org/10.1111/bjh.15453CrossRefPubMed

26.

Khazaal MS, Hamdan FB, Al-Mayah QS (2019) Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients. Mol Genet Genom Med 7(8):e809. https://doi.org/10.1002/mgg3.809CrossRef

27.

Vasconcelos A, Azevedo I, Melo F, Neves W, Azevedo A, Melo R (2017) BCR–ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia. Genet Mol Res 16(2):gmr16029541. https://doi.org/10.4238/gmr16029541CrossRef

28.

Al-Achkar W, Moassass F, Youssef N, Wafa A (2016) Correlation of p210 BCR–ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. J BUON 21(2):444–449PubMed

Title: Distribution of BCR–ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
Authors: Temilola O. Owojuyigbe
Muheez A. Durosinmi
Ramoni A. A. Bolarinwa
Lateef Salawu
Norah O. Akinola
Abdulwaheed A. Ademosun
Oluwayomi T. Bosede
Publication date: 01-10-2020
Publisher: Springer India
Keywords: Chronic Myeloid Leukemia
Imatinib
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-020-01264-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis

Surveillance of Transfusion Related Adverse Reactions in a Tertiary Care Centre in Bangalore: A 4-Year Hemovigilance Initiative

Splenectomy Modulates the Erythrocyte Turnover and Basigin (CD147) Expression in Mice

Post-transplant Hemophagocytic Lymphohistiocytosis in Benign Hematological Disorders: Experience of 4 Cases with Review of Literature

Morphology As a Guide to the Diagnosis of a Rare Cause of Neutropenia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer